The Castle Delivery Meeting Redux2. Delivery of Nucleic Acid Therapeutics: Biology, Engineering and Development. 2024. Siracusa, Sicily. Invited speaker
III Spanish meeting on Oligonucleotide Therapeutics (SMOT) “Networking is key in the development of nucleic acid therapeutics” Valencia, Spain, October 2023 Invited Speaker
EMBL in Spain: from Molecular to Systems Biology October 2023 Invited Speaker
Controlled Release Society – Italy Chapter “Nucleic acid therapeutics may change the way we treat disease, but not until we solve the delivery problem.” Palermo, Italy Oct 2023
European Joint Programme for Rare Disorders, “The delivery hurdle in the field of Nucleic Acids Therapeutics” June 2023 Vall d’Hebron Hospital Barcelona June 2023, Invited speaker
Duchenne Parent Project Spain, “La red europea DARTER y Duchenne Parent Project España: 5 años de resultados” June 2023, Invited speaker
Dutch Antisense Therapeutics Symposium “Networking is key in the development of nucleic acid therapeutics” June 2023, Invited speaker
Sociedad catalana de neurología, “Terapias de ácidos nucleicos en enfermedades neuromusculares” Barcelona, May 2023 Invited speaker
Diálogos Ikerbasque: “Terapias de ARN, sus aplicaciones y sus implicaciones éticas” May 2023 Online, Invited Speaker
COST Action Genome Editing to Treat Humans Diseases (GenE-Humdi) Inaugural Conference The delivery hurdle in the field of Nucleic Acids Therapeutics, March 2023 Invited Speaker
Sociedad Española de Neurología (SEN) “Terapias de ácidos nucleicos en enfermedades neurológicas” Seville, Nov 2022 Invited Speaker
Oligonucleotide Webinar series “An insider’s view into the preclinical development of an approved exon skipping drug” October 2022 Invited Speaker
Summer course on advanced therapies June 2022, San Sebastian, Invited speaker and moderator
European Society of Human Genetics (ESHG) Conference 2022, “Why don’t researchers publish “negative” results in genetics?” June 2022, Vienna. Invited speaker.
Neurosciences seminar series, CIMA. ¿Que les falta a las terapias de RNA para estar por todas partes? Pamplona, May 2022 Spain Invited speaker.
8th international therapeutic nucleic acids conference, Oligo 2022 “Delivery: a hurdle and the key to nucleic acid therapeutics’ success” April 2022, Oxford Invited Speaker
Meeting of the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT), “Clinical application of oligonucleotide-based splice site correction in Duchenne muscular dystrophy” (DMD) March 2022. Invited speaker
Academia de Ciencias médicas de Bilbao” ‘Medicina de precisión: empezando por lo poco habitual y alcanzando a todos’ October 2021. Invited speaker
Bio Türkiye “Delivery is key: lessons from developing splice switching oligonucleotides” 11 Sept 2021 (online)
Duchenne Parent project Spain Workshop (online) “Compartir resultados “negativos” puede ser positivo” 7 Sept 2021
DARTER Online Workshop “Open Access and “negative” results” July 2021
DARTER Training school “Unexpected but still valuable: why and how to communicate “negative results” June 2021
ICNMD 2021 “Dystrophin Quantification in Diagnostic Pathology and Clinical Trials: Implication for Diagnosis and Translational Research” Valencia (virtual) May 2021
Spanish cardiology society “Terapias avanzadas para enfermedades neuromusculares”, Málaga (virtual) Feb 2021
“Developing treatments for rare diseases: much more than finding a new drug” CIC-Biogune (online webinar) July 2020
“Developing treatments for rare diseases: much more than finding a new drug” IBIS Sevilla March 2020
Asociación Enfermos Neuromusculares de Bizkaia (BENE) “Avances y retos de la investigación” Terapia “genica” en DMD” Bilbao, Spain. Dec 2019
CORBI summit Encuentro de mujeres científicas. Lugo Dec 2019
Second Spanish Meeting on Oligonucleotide Therapeutics (SMOT2). “Delivery hurdles in the development of therapeutic oligonucleotides” INCLIVA, Valencia, Nov 2019
Reunión de primavera Neuromusculares, Sociedad Española Neurología. Bilbao, Mayo 2019.
XXXII Congreso nacional de Enfermedades Neuromusculares, Federación ASEM, Las Palmas, Mayo 2019
Jornada Cardiogenética Murcia, Nov 2018
First Spanish Meeting on Oligonucleotide Therapeutics (SMOT1). “Preclinical and clinical studies using oligonculeotide therapies in Duchenne” University of Valencia, June 2018. PDF.
I Congreso nacional sobre la distrofia muscular de Duchenne y Becker “Edición génica de células de modelos animales para un tránsito más rápido de la terapia a la clínica” Madrid, 26 May 2018
Webinar “Edición génica CRISPR/Case n las distrofias musculares de Duchenne y Becker” Duchenne Parent Project Spain, 8 Mayo 2018. Video.
VII Jornada científica, Federación de Enfermedades Raras FEDER, “Desarrollo de terapias para enfermedades raras” Bilbao, 18 Marzo 2018
Jakinmina “Developing treatments for rare diseases: much more than finding a new drug” Jakiunde, Academy of Sciences, Arts and Leters, Deusto Business School, 26 Jan 2018.
XXXI Congreso de Enfermedades Neuromusculares, Federación ASEM, Granada, November 2017. Video.
Science plus, ERA Career day, Bizkaia Aretoa, Bilbao September 2017. Video.
II Research Workshop Duchenne Parent Project Spain, “Research of the Neuromusuclar Disorders Group at IIS BioCruces” Barcelona, Spain. September 2017.
“Nuevas terapias en Distrofia muscular de Duchenne”, Pediatrics Service, Cruces University Hospital, Barakaldo, Spain June 2017.
Symposium “Todos somos raros”: “QUADRES: QUAntification of Dystrophin Restoration by Exon Skipping”, Spanish ministry of Health, Madrid, June 2017.
“Investigación en Distrofia muscular de Duchenne” Manzana solidaria, colegio Europa, Getxo 10 Mayo 2017.
“Estrategia topagunea: “Atraer, retener y vincular el talendo en Bizkaia” Estrategia empresarial y diputación de Bizkaia, BIC Barakaldo, Spain, April 2017.
Neurokafe, “Orphan drugs, rare diseases: a coffee break story” BioCruces Heatlh Research Institute, Barakaldo, Spain, February 2017.
RefBio Pyrenees Biomedical Network Elevator pitch “Quantification of target proteins in cell culture: how to accelerate the transit from the bench to the clinic”. Toulouse, January 2017.
Asociación Enfermos Neuromusculares de Bizkaia (BENE) “Avances y retos de la investigación” Bilbao, Spain. Diciembre 2016.
Reunión extraordinaria del grupo GEVANENEM: “Actualización en distrofinopatías y casos clínicos”. “Distrofinopatías: estado actual de las terapias basadas en salto del exón” San Sebastián November 2016.
Action Duchenne International Conference. “World Muscle Society Conference highlights” London, United Kingdom. November 2016.
Asociación Ayuda enfermedades raras solidaridad y esperanza Gipuzkoa “Obstáculos en el desarrollo de terapias para enfermedades raras” Azpeitia, Spain, October 2016.
Duchenne Parent Project Spain I Workshop trasferencia del conocimiento en la distrofia muscular de Duchenne, “Grupo Enfermedades Neuromusculares IIS BioCruces” Barcelona, Spain. September 2016
Seminar to the Pharmacy Department, Cruces University Hospital “Uso de terapia antisense como terapia: el ejemplo de la distrofia muscular de Duchenne” Barakaldo, Spain. March 2016
BioCruces Neuroscience Area Invited seminar “Uso de terapia antisense como terapia: el ejemplo de la distrofia muscular de Duchenne” Cruces University Hospital, Barakaldo, Spain. January 2016
8th Biennial Congress of the Spanish Society for Gene and Cell Therapy, San Sebastián, Spain. “Antisense-mediated splicing modulation in neuromuscular disorders” Nov 2015
Jornadas ASEM Catalunya (Associació Catalana de Malalties Neuromusculars) “Investigación en enfermedades neuromusculares” Barcelona, June 2015
Invited seminar “Terapias avanzadas: más cerca de la clínica de lo que parece.” Galdakao Hospital, Spain. May 2015
Horizon 2020 Infoday: Basque success stories “Applying for Marie Curie Fellowships” BEC Barakaldo, Spain. January 2014
Congress of the Spanish Neurology Society, “Terapia de RNA en enfermedades neuromusculares: salto del exón en la distrofia muscular de Duchenne” Barcelona, Spain. November 2013
International Symposium Ramon Areces Foundation, Madrid, Spain ” Current concepts over antisense therapeutic strategies. Clinical Trials.” (http://goo.gl/Fafbn) November 2012. Video.
XXVI Congress of the Spanish Human Genetics Association, Spain “RNA Therapy in Duchenne muscular dystrophy: exon skipping” April 2011
7th Christmas Meeting, Neurosciences Institute, Alicante, Spain. “Exon skipping with antisense oligonucleotides: Restoration of dystrophin expression in Duchenne muscular dystrophy” December 2010.
Hospital de Cruces, Bizkaia, Spain “RNA therapy in Duchenne muscular dystrophy” December 2010.
Parent Project conference, Rome, Italy. “Restoration of Dystrophin Expression in DMD Using Morpholino Oligomer AVI-4658” February 2010.
London Myology forum, UK. “Local restoration of dystrophin expression in Duchenne Muscular Dystrophy” November 2009.
14th International Congress of the World Muscle Society, Geneva, Switzerland. “Restoration of Dystrophin Expression in Duchenne Muscular Dystrophy: A Single Blind, Placebo-Controlled Dose Escalation Study Using Morpholino Oligomer AVI-4658”. Neuromuscular Disorders September 2009 (Vol. 19, Issue 8, Page 659).
